Rituximab in Membranous Nephropathy: Is It a First-Line Treatment?

被引：8
|
作者：
Appel, Gerald B. [1 ]
机构：
[1] Columbia Univ, Med Ctr, Columbia Univ Coll Phys & Surg, Dept Med,Div Nephrol, New York, NY 10032 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2012年 / 23卷 / 08期
关键词：
THERAPY; ANTIGEN;
D O I：
10.1681/ASN.2012060602
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1280 / 1282
页数：3
相关论文
共 50 条
  • [31] Superiority of Rituximab Over Mycophenolate Mofetil in the Treatment of Pemphigus Vulgaris: A Step Further in Its Approval as a First-Line Treatment?
    Lemieux, Alexandre
    Saber, Melissa
    Cote, Benoit
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2022, 26 (01) : 103 - 104
  • [32] Low-Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy
    Cravedi, P.
    Ruggenenti, P.
    Remuzzi, G.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1336 - 1336
  • [33] Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis
    Huang, Lan
    Dong, Qiao-Rong
    Zhao, Ya-Juan
    Hu, Gui-Cai
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (01) : 111 - 119
  • [34] Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients
    Kianfar, Nika
    Dasdar, Shayan
    Mahmoudi, Hamidreza
    Tavakolpour, Soheil
    Balighi, Kamran
    Daneshpazhooh, Maryam
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 869 - 874
  • [35] Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study
    Cravedi, Paolo
    Sghirlanzoni, Maria Chiara
    Marasa, Maddalena
    Salerno, Alessandra
    Remuzzi, Giuseppe
    Ruggenenti, Piero
    AMERICAN JOURNAL OF NEPHROLOGY, 2011, 33 (05) : 461 - 468
  • [36] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [37] Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study
    Malard, Florent
    Labopin, Myriam
    Yakoub-Agha, Ibrahim
    Chantepie, Sylvain
    Guillaume, Thierry
    Blaise, Didier
    Tabrizi, Reza
    Magro, Leonardo
    Vanhove, Bernard
    Blancho, Gilles
    Moreau, Philippe
    Gaugler, Beatrice
    Chevallier, Patrice
    Mohty, Mohamad
    BLOOD, 2017, 130 (20) : 2186 - 2195
  • [38] Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial
    Scolari, Francesco
    Dallera, Nadia
    Gesualdo, Loreto
    Santoro, Domenico
    Pani, Antonello
    Santostefano, Marisa
    Feriozzi, Sandro
    Mani, Laila-Yasmin
    Boscutti, Giuliano
    Messa, Piergiorgio
    Magistroni, Riccardo
    Quaglia, Marco
    Ponticelli, Claudio
    Ravani, Pietro
    BMJ OPEN, 2019, 9 (12):
  • [39] Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
    Zhong, Hongzhen
    Li, Hong-Yan
    Zhou, Tianbiao
    Zhong, Zhiqing
    ARCHIVES OF MEDICAL SCIENCE, 2023, 19 (02) : 411 - 419
  • [40] Rituximab in primary membranous nephropathy: a comparative study of three dosing regimens
    Ramachandran, Raja
    Nayak, Saurabh
    Kumar, Vinod
    Sethi, Jasmine
    Minz, Ranjana
    Kumar, Vivek
    Rathi, Manish
    Kohli, Harbir Singh
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (07) : 1352 - 1354
12345